<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:e sem="disease" ids="C1719470" disease_type="Disease or Syndrome" abbrv="">Broken-heart syndrome</z:e> also known as Left ventricular apical ballooning syndrome or Stress-induced <z:hpo ids='HP_0001638'>cardiomyopathy</z:hpo> or <z:hpo ids='HP_0011665'>Takotsubo cardiomyopathy</z:hpo> is an important clinical entity, which presents clinically, similar to <z:hpo ids='HP_0011009'>acute</z:hpo> coronary syndrome with an <z:hpo ids='HP_0011009'>acute onset</z:hpo> of <z:hpo ids='HP_0100749'>chest pain</z:hpo>, ST-T changes in electrocardiogram, and moderate cardiac enzyme elevation </plain></SENT>
<SENT sid="1" pm="."><plain>Recent studies have shown that it accounts for 1%-2% of cases of ST-elevation infarction </plain></SENT>
<SENT sid="2" pm="."><plain>An episode of intense emotional or physiologic stress has been reported before its presentation and is presumed to be the triggering factor in the pathogenesis </plain></SENT>
<SENT sid="3" pm="."><plain>The pathophysiology of this syndrome still remains unclear, and management is mostly empiric and supportive </plain></SENT>
<SENT sid="4" pm="."><plain>In this review, we have discussed various pathophysiologic mechanisms underlying this <z:hpo ids='HP_0001638'>cardiomyopathy</z:hpo> and their pharmacological implications and role of medications such as aspirin, beta blockers, <z:chebi fb="0" ids="35457">angiotensin-converting enzyme inhibitors</z:chebi>, and <z:chebi fb="0" ids="35664">statins</z:chebi> for patients presenting with this syndrome in treatment and prevention </plain></SENT>
</text></document>